Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

INTRODUCTION: Golimumab, a monoclonal antibody against tumor necrosis factor–α (TNF-α), is used widely for treatment of rheumatic diseases. Long-term persistence is an important factor influencing therapeutic benefit and is a surrogate measure of efficacy. We compared five-year golimumab treatment p...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinstein, Cindy L. J., Meehan, Alan G., Lin, Jianxin, Briscoe, Steven D., Govoni, Marinella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640568/
https://www.ncbi.nlm.nih.gov/pubmed/37751000
http://dx.doi.org/10.1007/s10067-023-06760-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640568/
https://www.ncbi.nlm.nih.gov/pubmed/37751000
http://dx.doi.org/10.1007/s10067-023-06760-z

Ejemplares similares